Declared bankruptcy in Oct 2023
NBRV - Nabriva Therapeutics plc
NASDAQ
->
Healthcare
->
Biotechnology
Dublin,
Ireland
Type: Equity
NBRV price evolution
NBRV
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.92 | $12.54 | $14.77 | $20.16 |
| Short term investments | ||||
| Net receivables | $10.51 | $6.74 | $12.39 | $12.36 |
| Inventory | $9.03 | $9.68 | $17.33 | $15.54 |
| Total current assets | $23.69 | $31.1 | $47.56 | $54.3 |
| Long term investments | ||||
| Property, plant & equipment | $0.26 | $0.28 | $0.29 | $0.21 |
| Goodwill & intangible assets | $0 | $0 | $0.01 | $0.01 |
| Total noncurrent assets | $0.64 | $0.66 | $0.68 | $0.6 |
| Total investments | ||||
| Total assets | $24.34 | $31.77 | $48.24 | $54.89 |
| Current liabilities | ||||
| Accounts payable | $6.98 | $5.43 | $3.9 | $1.07 |
| Deferred revenue | ||||
| Short long term debt | $0.2 | $4.83 | $5.73 | $6.62 |
| Total current liabilities | $28 | $27.61 | $21.64 | $19.33 |
| Long term debt | $0.34 | $0.39 | $0.4 | $0.51 |
| Total noncurrent liabilities | $0.7 | $0.87 | $0.98 | $0.96 |
| Total debt | $0.54 | $5.22 | $6.13 | $7.14 |
| Total liabilities | $28.7 | $28.47 | $22.62 | $20.29 |
| Shareholders' equity | ||||
| Retained earnings | -$661.56 | -$652.86 | -$630.08 | -$618.57 |
| Other shareholder equity | $0.03 | $0.03 | $0.03 | $0.03 |
| Total shareholder equity | -$4.36 | $3.29 | $25.62 | $34.6 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.54 | $47.83 | $41.59 | $86.41 |
| Short term investments | $0.02 | $0.02 | $0.17 | |
| Net receivables | $6.74 | $12.75 | $4.28 | $3.12 |
| Inventory | $9.68 | $14.51 | $5.82 | $0.68 |
| Total current assets | $31.1 | $80.27 | $57.22 | $91.17 |
| Long term investments | ||||
| Property, plant & equipment | $0.28 | $0.23 | $0.77 | $2.47 |
| Goodwill & intangible assets | $0 | $0.03 | $0.08 | $0.09 |
| Total noncurrent assets | $0.66 | $0.64 | $1.22 | $2.94 |
| Total investments | $0.02 | $0.02 | $0.17 | |
| Total assets | $31.77 | $80.91 | $58.44 | $94.11 |
| Current liabilities | ||||
| Accounts payable | $5.43 | $4.37 | $2.89 | $4.67 |
| Deferred revenue | $0.37 | $0.75 | ||
| Short long term debt | $4.83 | $3.77 | $2.04 | |
| Total current liabilities | $27.61 | $22.34 | $18.52 | $16.64 |
| Long term debt | $0.39 | $4.26 | $5.69 | $34.5 |
| Total noncurrent liabilities | $0.87 | $5.22 | $6.78 | $36.2 |
| Total debt | $5.22 | $8.03 | $7.73 | $34.5 |
| Total liabilities | $28.47 | $27.56 | $25.3 | $52.84 |
| Shareholders' equity | ||||
| Retained earnings | -$652.86 | -$595.68 | -$546.23 | -$476.74 |
| Other shareholder equity | $0.03 | $0.03 | $0.03 | $0.03 |
| Total shareholder equity | $3.29 | $53.35 | $33.13 | $41.27 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.59 | $10.57 | $9.15 | $9.19 |
| Cost of revenue | $4.44 | $16.35 | $4.42 | $4.46 |
| Gross Profit | $3.15 | -$5.78 | $4.74 | $4.74 |
| Operating activities | ||||
| Research & development | $2.63 | $2.63 | $4.03 | $4.09 |
| Selling, general & administrative | $9 | $9.61 | $11.91 | $11.05 |
| Total operating expenses | $11.63 | $12.24 | $15.94 | $15.13 |
| Operating income | -$8.47 | -$18.01 | -$11.2 | -$10.4 |
| Income from continuing operations | ||||
| EBIT | -$8.51 | -$22.33 | -$10.85 | -$10.49 |
| Income tax expense | $0.31 | $0.52 | $0.39 | |
| Interest expense | $0.19 | $0.14 | $0.15 | $0.2 |
| Net income | ||||
| Net income | -$8.7 | -$22.78 | -$11.51 | -$11.07 |
| Income (for common shares) | -$8.7 | -$22.78 | -$11.51 | -$11.07 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.94 | $28.89 | $5.03 | $9.48 |
| Cost of revenue | $28.58 | $13.15 | $0.77 | $0.07 |
| Gross Profit | $8.35 | $15.75 | $4.26 | $9.41 |
| Operating activities | ||||
| Research & development | $14.26 | $12.63 | $15.1 | $26.41 |
| Selling, general & administrative | $45.26 | $51.65 | $55.28 | $62.48 |
| Total operating expenses | $59.53 | $64.28 | $70.39 | $88.9 |
| Operating income | -$51.17 | -$48.53 | -$66.13 | -$79.49 |
| Income from continuing operations | ||||
| EBIT | -$54.92 | -$48.06 | -$67.61 | -$79.02 |
| Income tax expense | $1.57 | $0.49 | $0.14 | $0.1 |
| Interest expense | $0.7 | $0.9 | $1.74 | $3.64 |
| Net income | ||||
| Net income | -$57.19 | -$49.45 | -$69.48 | -$82.76 |
| Income (for common shares) | -$57.19 | -$49.45 | -$69.48 | -$82.76 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$8.7 | -$22.78 | -$11.51 | -$11.07 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.03 | $0.04 | $0.08 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1 | $0.14 | $0.5 | $0.33 |
| Total cash flows from operations | -$5.62 | -$1.63 | -$6.18 | -$13.04 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.01 | -$0.1 | -$0.06 |
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.01 | -$0.1 | -$0.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.08 | $0.4 | ||
| Net borrowings | -$4.85 | -$0.62 | $1.11 | -$0.55 |
| Total cash flows from financing | -$4.85 | -$0.66 | $1.11 | -$0.79 |
| Effect of exchange rate | -$0.14 | $0.06 | -$0.22 | $0.15 |
| Change in cash and equivalents | -$10.62 | -$2.23 | -$5.39 | -$13.79 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$57.19 | -$49.45 | -$69.48 | -$82.76 |
| Operating activities | ||||
| Depreciation | $0.22 | $0.36 | $0.82 | $0.77 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.97 | $3.29 | $5.22 | $9.75 |
| Total cash flows from operations | -$36.71 | -$59.56 | -$71.33 | -$71.89 |
| Investing activities | ||||
| Capital expenditures | -$0.21 | -$0.03 | -$0.11 | -$0.06 |
| Investments | ||||
| Total cash flows from investing | -$0.26 | -$0.08 | -$0.27 | $0.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.12 | $27.91 | $54.17 | $20.51 |
| Net borrowings | $0.54 | $42.28 | -$22.48 | $37.92 |
| Total cash flows from financing | $1.85 | $66.37 | $26.92 | $56.08 |
| Effect of exchange rate | -$0.17 | -$0.48 | -$0.14 | -$0.11 |
| Change in cash and equivalents | -$35.3 | $6.24 | -$44.82 | -$15.59 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.20M |
| Revenue | $36.51M |
|---|---|
| EBITDA | -$52.02M |
| EBIT | -$52.17M |
| Net Income | -$54.07M |
| Revenue Q/Q | -5.36% |
| Revenue Y/Y | 6.16% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -1.37 |
| Cash/Share | 0.60 |
| EPS | -$16.89 |
|---|---|
| ROA | -135.81% |
| ROE | -365.53% |
| Debt/Equity | 8.65 |
|---|---|
| Net debt/EBITDA | -0.51 |
| Current ratio | 0.85 |
| Quick ratio | 0.52 |